Antiamyloid Gantenerumab Disappoints in Phase 3 Trials ...Middle East

Medscape - News
The antiamyloid monoclonal antibody gantenerumab led to a lower amyloid plaque burden but no clear cognitive benefit in early Alzheimer's disease in twin pivotal trials. Medscape Medical News

Hence then, the article about antiamyloid gantenerumab disappoints in phase 3 trials was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antiamyloid Gantenerumab Disappoints in Phase 3 Trials )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News